At the Society for Immunotherapy of Cancer’s annual meeting, researchers from Tallac Therapeutics Inc. reported the discovery of TAC-003, a novel Toll-like receptor 9 (TLR9) agonist and Nectin-4-specific antibody conjugate, being developed as cancer immunotherapy candidate.
Scientists at the University of California San Francisco (UCSF) have designed a group of synthetic molecules that could prevent the rejection of allogeneic cell transplants. Their strategy consisted of activating the immune checkpoints of different populations of immune cells from the cell surface, but avoiding the cytotoxicity of natural killer (NK) cells and macrophages that would destroy the transplanted cells.
New and updated preclinical data presented at the Society for Immunotherapy of Cancer congress in San Diego, by: Akeso, Antengene, Asher Biotherapeutics, Bioinvent International, Carisma Therapeutics, Catalym, Coeptis Therapeutics, Context Therapeutics, Corbus Pharmaceuticals, Gracell Biotechnologies, Lyell Immunopharma.
Corbus Pharmaceuticals Holding Inc. has described cannabinoid CB1 receptor antagonists or inverse agonists reported to be useful for the treatment of cancer, dyslipidemia, diabetes, obesity, cardiovascular, inflammatory and liver diseases.
Alesta Therapeutics BV has identified eukaryotic translation initiation factor 2-α kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer.
Uniquest Pty Ltd. has synthesized tyrosine-protein kinase SYK inhibitors reported to be useful for the treatment of allergy, cancer, fungal infections, rheumatoid arthritis, osteoporosis, liver, lung and periodontal diseases, among others.
Brenig Therapeutics Inc. has disclosed leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease, among others.
RSS
